Lipoprotein
Laboratory Measurement
Cholesterol and Atherogenesis
Lipid and Lipoprotein Basics
Clinical Lipid Management
Successful early studies reported for two Lp(a)-lowering therapies
The first oral treatment to lower lipoprotein(a) safely lowered Lp(a) in a phase 1 study, whereas an extended phase 2 study showed durable Lp(a) lowering by an injectable treatment, researchers reported.
VIDEO: Lp(a) testing often warranted, but how to treat high levels unclear
ARLINGTON, Texas — In this Healio video exclusive, an expert breaks down a session on the significance of lipoprotein(a) at the American Society for Preventive Cardiology Congress on CVD Prevention.
VIDEO: The latest in lipid-lowering therapy at NLA with Christie M. Ballantyne
In this Healio | Cardiology Today video exclusive, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It's Not Just a Phase.”
Lp(a) level varies widely among Hispanic US adults
Median lipoprotein(a) levels vary widely among Hispanic or Latino U.S. adults, with the highest median values seen among those self-identifying as Cuban, Dominican or Puerto Rican, researchers reported.
Lipoprotein(a): The next frontier in CV risk reduction
This installment of Pipeline Pulse focuses on a single cardiovascular risk factor, lipoprotein(a), and examines two CV outcomes trials aimed at reducing CV events through Lp(a) reduction.
Supplements touting CV benefits may be ‘harmful distraction’ from proven solutions
Dietary supplements are big business in the United States and elsewhere, especially when it comes to products marketed to support CV health.